Targeting the senescence-associated secretory phenotype to modify osteoarthritis in aging
Inflammopharmacology · 2025-11 · 33 (11) · 6555-6575
DOI: 10.1007/s10787-025-02001-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Inflammopharmacology, online erschienen am 11.10.2025. Verfasst von Muhammad Afzal und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, 21442, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Osteoarthritis, Aging, Senescence-Associated Secretory Phenotype. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 162 Literaturangaben.
Abstract (Originalsprache)
Osteoarthritis (OA) is a common joint condition correlated with aging, characterized by the gradual degradation of cartilage, alterations in the subchondral bone, and ongoing low-level inflammation. There is growing evidence that the senescence-associated secretory phenotype (SASP) of chondrocytes, which includes the continuous release of IL1β, IL6, TNFα, MMP3, and MMP13, offers a crucial function in driving the pathology of OA. In this review, we consolidate the existing knowledge on the molecular processes that lead to chondrocyte aging, such as NFκB/MAPK signaling, oxidative stress, mitochondrial dysfunction, and epigenetic changes. We also critically assess senotherapeutic strategies, including senolytics (dasatinib + quercetin, ABT263), senomorphics (rapamycin, metformin, pterostilbene), anti-oxidant nanomaterials, and therapies based on extracellular vesicles that specifically reduce SASP while maintaining cartilage health. This study looks at SASP biomarkers in different joint tissues. It also examines how nanotechnology and EV strategies can help renew aging chondrocytes. This review examines the impact of cartilage changes on the aging process. It offers guidance on delaying osteoarthritis, identifies early indicators, and proposes innovative treatments to maintain joint health as grow older.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, 21442, Jeddah, Saudi Arabia.
- School of Pharmaceutical Sciences, Swami Rama Himalyan University, Swami Rama Nagar, Jolly Grant, Dehradun, India.
- Department of Chemistry & Biochemistry, School of Sciences, JAIN (Deemed to be University), Bengaluru, Karnataka, India.
- Department of General Medicine, IMS & SUM Hospital, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, India.
- Department of Pharmacology, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India.
- Noida Institute of Engineering and Technology (Pharmacy Institute), 19 Knowledge Park 2, Greater Noida, India.
Zitieren
APA
Afzal, M., Rekha, M. M., Sahoo, S., Pandey, S. N., Maji, C., Goyal, K., Ali, H., Singh, S. K., Gupta, G., & Hussain, M. S. (2025). Targeting the senescence-associated secretory phenotype to modify osteoarthritis in aging. Inflammopharmacology, 33(11), 6555-6575. https://doi.org/10.1007/s10787-025-02001-8
Vancouver
Afzal M, Rekha MM, Sahoo S, Pandey SN, Maji C, Goyal K, et al. Targeting the senescence-associated secretory phenotype to modify osteoarthritis in aging. Inflammopharmacology. 2025;33(11):6555-6575. doi:10.1007/s10787-025-02001-8
BibTeX
@article{Afzal2025,
author = {Afzal, Muhammad and Rekha, M M and Sahoo, Samir and Pandey, Surya Nath and Maji, Chandana and Goyal, Kavita and Ali, Haider and Singh, Sachin Kumar and Gupta, Gaurav and Hussain, Md Sadique},
title = {Targeting the senescence-associated secretory phenotype to modify osteoarthritis in aging},
journal = {Inflammopharmacology},
year = {2025},
volume = {33},
number = {11},
pages = {6555--6575},
doi = {10.1007/s10787-025-02001-8}
}
EUVIMED